中西医结合治疗非小细胞肺癌研究进展  

Combined Therapy of Traditional Chinese and Western Medicine to Treat Non-Small-Cell Lung Cancer: A Review

作　　者：叶俊宏 文曦儿 陈立义 林嘉豪 陈小鑫 宋天河 施祖荣[1] 张樟进[1] 张艳波[1] 

机构地区：[1]香港大学中医药学院,香港薄扶林

出　　处：《中医学》2018年第2期142-146,共5页Traditional Chinese Medicine

摘　　要：非小细胞型肺癌(non-small-cell lung cancer,简称NSCLC)是肺部恶性肿瘤之一。NSCLC个案占整体肺癌患者约85%,而其中约70%患者确诊时已属晚期,出现转移无法以手术根治。现代医学治疗方法有放疗、化疗、生物治疗及介入治疗等,但未能有效提高患者生存率。按近年研究和临床实验显示,中西医结合治疗能降低因治疗肺癌而造成的毒副作用和伤害,并能控制肿瘤增生、复发、转移情况,从而延长生存期。本文就中西医结合治疗NSCLC研究进展作综合论述。Lung carcinoma is one of the leading caners with high mortality rate and poor prognosis in Hong Kong and worldwide. The prevalence of Non-small-cell lung cancer (NSCLC) is 85% among the diagnosed cases, where 70% are metastatic and incurable. Diverse medications, including radio-therapy, chemotherapy, biotherapy and interventional treatments, are available in clinic. However, the survival rate of lung cancer patients is failed to improve sufficiently. According to recent research and clinical reports, integrating traditional Chinese and western medicine induce cancer-cell apoptosis, reduce recurrence and metastatic rate of NSCLC. Essentially, the new management helps to diminish therapeutic side effects, relieve physical pain and prolong the life expectancy. This review will focus on the potential advantages towards the patients by combining Chinese and Western medicine to treat non-small-cell lung cancer.

关 键 词：中西医结合 非小细胞肺癌 肺癌 疗效 

分 类 号：R73[医药卫生—肿瘤]